Allergopharma J. Ganzer KG Pharmazeutische Erzeugnisse Information

Allergopharma was founded in 1969 by Hermal and Joachim Ganzer in Reinbek near Hamburg. Today the company has more than 480 employees, including 60 in research. Allergopharma was fully integrated into Merck as the Allergy business unit in 2013. By leveraging its expertise as a global company, Merck aims to expand its Allergy business unit internationally, strengthen it in Europe as well as develop new products, and intends to invest significantly in this market segment. The Allergopharma success story is based primarily on hypoallergenic, high-dose products (allergoids) that can be used either preseasonally or perennially. Major benefits of subcutaneous specific immunotherapy (SCIT) that Allergopharma mainly offers are a close patient-doctor relationship, good patient compliance, good efficacy and a favorable cost-benefit ratio. Allergopharma is the global market leader in this field. Allergen-specific immunotherapy (SIT), also known as hyposensitization or desensitization, allergy vaccination, is largely recognized as the only causal treatment for allergies to unavoidable allergens. Demanding and living up to the highest of quality standards and committed to ongoing allergy product improvement, Allergopharma has developed from a pharmaceutical company into an international leader in SIT research. As a leader in innovative recombinant ("bio-engineered") allergens, Allergopharma is also ready for the future.